NASDAQ:IMPL Impel Pharmaceuticals (IMPL) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free IMPL Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.04▼$0.8452-Week Range N/AVolume720,000 shsAverage Volume682,655 shsMarket Capitalization$956,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get Impel Pharmaceuticals alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Impel Pharmaceuticals Stock (NASDAQ:IMPL)Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.Read More Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. IMPL Stock News HeadlinesMarch 13, 2024 | finance.yahoo.comImpel Pharmaceuticals Inc. (IMPLQ)December 20, 2023 | markets.businessinsider.comImpel Pharma Mulls Sale, Signs Stalking Horse Deal; Files For Chapter 11 ProtectionApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.December 20, 2023 | finance.yahoo.comImpel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate SaleNovember 6, 2023 | bizjournals.comAdrian Adams steps down as CEO of Seattle's Impel PharmaceuticalsOctober 9, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Impel Pharmaceuticals (IMPL) and Relay Therapeutics (RLAY)October 5, 2023 | finance.yahoo.comImpel Pharmaceuticals Announces Exploration of Strategic AlternativesSeptember 14, 2023 | markets.businessinsider.comImpel Pharmaceuticals (IMPL) Receives a Hold from JonesTradingApril 26, 2024 | DTI (Ad)What is the 72-Hour Profit Surge?One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…September 8, 2023 | msn.comWhy Is Impel Pharmaceuticals (IMPL) Stock Up 32% Today?August 22, 2023 | markets.businessinsider.comJonesTrading Reaffirms Their Hold Rating on Impel Pharmaceuticals (IMPL)August 16, 2023 | marketwatch.comImpel Pharma Shares Tumble 46% After Breaching Terms of Credit AgreementAugust 16, 2023 | msn.comImpel Pharma (NASDAQ:IMPL) Plummets on Viability ConcernsAugust 16, 2023 | investorplace.comWhy Is Impel Pharmaceuticals (IMPL) Stock Down 35% Today?July 5, 2023 | theglobeandmail.comBiotech Catches Major Premarket BidJuly 3, 2023 | finance.yahoo.com84P.SG - Impel Pharmaceuticals IncJune 21, 2023 | benzinga.comDirector at Impel Pharmaceuticals Acquires Company Stock Options Worth 13,222 SharesJune 21, 2023 | benzinga.comImpel Pharmaceuticals Board Member Awarded $15K Worth of Stock OptionsJune 21, 2023 | benzinga.comImpel Pharmaceuticals Director Awarded $15K Worth of Stock OptionsJune 15, 2023 | finance.yahoo.comImpel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache SocietyMay 17, 2023 | uk.finance.yahoo.comImpel Pharmaceuticals Inc. (IMPL)May 13, 2023 | finance.yahoo.comImpel Pharmaceuticals First Quarter 2023 Earnings: Misses ExpectationsMay 12, 2023 | msn.comRecap: Impel Pharmaceuticals Q1 EarningsMay 12, 2023 | finance.yahoo.comImpel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business UpdateMay 11, 2023 | msn.comEarnings Outlook For Impel PharmaceuticalsMay 10, 2023 | msn.comImpel Pharmaceuticals gets new CFOMay 10, 2023 | finance.yahoo.comImpel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial OfficerSee More Headlines Receive IMPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMPL CUSIPN/A CIK1445499 Webwww.Impelnp.com Phone206-568-1466FaxN/AEmployees160Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,310,000.00 Net Margins-353.93% Pretax Margin-353.93% Return on EquityN/A Return on Assets-127.43% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.13 Sales & Book Value Annual Sales$20.99 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($1.86) per share Price / BookN/AMiscellaneous Outstanding Shares23,900,000Free Float22,418,000Market Cap$956,000.00 OptionableNot Optionable Beta1.17 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Leonard S. Paolillo (Age 44)Interim President & CEO Comp: $523.97kDr. John D. Hoekman Ph.D. (Age 42)Co-Founder and Chief Technology & Development Officer Mr. Michael W. Kalb CPA (Age 52)Chief Financial Officer Ms. Jennifer L. BermanVice President of MarketingMs. Sarah WilleVice President of Human ResourcesDr. Lynn C. Gold Ph.D. (Age 66)Senior Vice President of Regulatory Mr. Scott Youmans (Age 56)Senior Vice President of Technical Operations More ExecutivesKey CompetitorsSciSparcNASDAQ:SPRCBiodexa PharmaceuticalsNASDAQ:BDRXEvofem BiosciencesNASDAQ:EVFMEvelo BiosciencesNASDAQ:EVLOBellerophon TherapeuticsNASDAQ:BLPHView All CompetitorsInsidersVivo Capital Viii, LlcSold 237,711 sharesTotal: $26,148.21 ($0.11/share)Vivo Capital Viii, LlcSold 100,000 sharesTotal: $29,000.00 ($0.29/share)View All Insider Transactions IMPL Stock Analysis - Frequently Asked Questions How were Impel Pharmaceuticals' earnings last quarter? Impel Pharmaceuticals Inc. (NASDAQ:IMPL) issued its quarterly earnings results on Monday, November, 15th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by $0.42. The company had revenue of $0.09 million for the quarter. When did Impel Pharmaceuticals IPO? Impel Pharmaceuticals (IMPL) raised $80 million in an IPO on Friday, April 23rd 2021. The company issued 5,300,000 shares at $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow acted as the underwriters for the IPO. This page (NASDAQ:IMPL) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThese AI trades triggered this morning (545% return)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Impel Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
